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OBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension
continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have
been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the
current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For
patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was
added to the traditional treatment, and hydrochlorothiazide was added to the current treatment.
METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive
medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure
(in mm Hg) at the end of a 12-month study period.
RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional
treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In
the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and
the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the
same pattern when the purchase price of the lower-cost medication was used.
CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current
treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and
the current treatment for the HT3 group.
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INTRODUCTION
Studies have demonstrated that hypertension is a major
health problem that is associated with high morbidity and
mortality rates, and the costs associated with hypertension
continue to increase (1,2). In most western countries, the
costs of hypertension treatment account for a substantial
portion of health resources (3).
Hypertension is also a significant issue in Brazil, and
diseases related to hypertension are responsible for high
hospitalization rates (4). Nevertheless, Brazilian pharma-
coeconomic studies related to hypertension have been rare
(5). The few studies that have examined antihypertensive
treatment costs in Brazil concluded that diuretics and
beta-blockers are more cost-effective than other classes of
antihypertensive drugs (6).
To date, no pharmacoeconomic studies have analyzed the
cost-effectiveness (C/E) ratio of antihypertensive drug
combinations, which are recommended by several interna-
tional guidelines for hypertension treatment (4,7).
Antihypertensive drug combinations were designed to
provide better control of hypertension, reduce the occa-
sional adverse effects, improve treatment compliance in
patients, and potentially reduce costs (8).
The objective of the present study was to evaluate the C/E
ratios of two antihypertensive therapeutic drug combina-
tions (i.e., hydrochlorothiazide plus atenolol versus losar-
tan plus amlodipine) in patients with different grades of
hypertension.
MATERIAL AND METHODS
Study Design
The economic analysis in this study was based on the
results of a randomized open clinical trial that compared
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two antihypertensive drug combinations: a thiazide diuretic
plus a beta-blocker and a calcium channel blocker plus an
angiotensin II receptor antagonist. Randomization was
performed by means of drawing from envelopes, and the
patients were followed for a period of 12 months (9).
The patients in the present study were referred to the
Hypertension Unit of the University of Sa˜o Paulo General
Hospital. The research protocol was approved by the Ethics
Committee of the University of Sa˜o Paulo General Hospital.
After receiving an explanation of the study, all of the
patients signed a free and informed consent form to
participate in the study.
Inclusion and exclusion criteria
This study included male and female patients who were
diagnosed with essential hypertension and were older than
18 years. Patients with a body mass index .40 kg/m2,
diabetes mellitus, chronic kidney disease, congestive heart
failure, coronary artery disease, and/or stroke were
excluded.
After the selection, the patients were categorized into two
groups on the basis of their blood pressure in accordance
with the European Society of Hypertension classification (7):
N Grade 1 and 2 hypertension (HT1-2): systolic blood
pressure (SBP) $140 mm Hg and ,180 mm Hg and/or
diastolic blood pressure (DBP) $90 mm Hg and
,110 mm Hg.
N Grade 3 hypertension (HT3): SBP $180 mm Hg and/or
DBP $110 mm Hg.
Study Protocol
The drug treatments evaluated by this pharmacoeco-
nomic analysis were based on combinations of low doses of
two or more classes of antihypertensive drugs. The
traditional treatment (TT) was based on the combination
of a thiazide diuretic (hydrochlorothiazide) with a beta-
blocker (atenolol) for the HT1-2 group, and an angiotensin-
converting enzyme inhibitor (enalapril) was added to the
treatment cocktail for the HT3 group. The current treatment
(CT) was based on the combination of an angiotensin II
receptor antagonist (losartan) with a dihydropyridine-type
calcium channel blocker (amlodipine) for the HT1-2 group,
and a diuretic thiazide (hydrochlorothiazide) was added to
the treatment cocktail for the HT3 group.
The patients were randomized to receive either the TT or
the CT regimen. When blood pressure (BP) control was not
achieved (SBP,140 mm Hg and/or DBP,90 mm Hg),
treatment steps were changed according to the protocols
shown below:
N Drug treatment regimens for the HT1-2 group:
Step 1 BP $ 140/90 TT atenolol 25 mg + HCTZ 6.25 mg –
twice a day
CT amlodipine 2.5 mg + losartan 25 mg - twice a day
Step 2 BP $ 140/90 TT atenolol 50 mg + HCTZ 12.5 mg -
twice a day
CT amlodipine 5 mg + losartan 50 mg - twice a day
Step 3 BP $ 140/90 TT atenolol 50 mg + HCTZ 12.5 mg +
enalapril 10 mg - twice a day
CT amlodipine 5 mg + losartan 50 mg + HCTZ 12.5 mg -
twice a day
N Drug treatment regimens for the HT3 Group:
Step 1 BP$ 180/110 TT atenolol 50 mg + enalapril 10 mg +
HCTZ 6.25 mg - twice a day
CT amlodipine 2.5 mg + losartan 25 mg + HCTZ 6.25 mg -
twice a day
Step 2 BP$ 140/90 TT atenolol 100 mg + enalapril 20 mg +
HCTZ 12.5 mg - twice a day
CT amlodipine 5 mg + losartan 50 mg + HCTZ 12.5 mg -
twice a day
Step 3 BP$ 140/90 TT atenolol 100 mg + enalapril 20 mg +
HCTZ 12.5 mg + clonidine 0.1 mg - twice a day
CT amlodipine 5 mg + losartan 50 mg + HCTZ 12.5 mg +
clonidine 0.1 mg - twice a day
During the 12-month follow-up period, each patient was
scheduled for seven medical visits with a 60-day interval
between each appointment. Occasionally, unscheduled
medical appointments had to be made for patients present-
ing a clinical intercurrence.
The total amount of medication necessary for 12 months
of treatment was supplied to the patients at the end of each
visit. Because 10% more pills were supplied, the remaining
pills were counted at the next visit, and adherence was
calculated on the basis of the number of remaining pills.
Any possible drug combinations that were not foreseen in
the study protocol were named ‘‘other combined treat-
ments’’ (OCTs). Thus, several combinations were possible at
the end of the study as a result of reductions in drug doses
and withdrawal or inclusion of other antihypertensive
drugs because the initial drugs were ineffective or caused
adverse side effects.
Pharmacoeconomic Study
Cost analysis. The management of adverse events
(exchanging antihypertensive medication, increasing or
reducing the dose, doses of drugs not specified in the
original protocol), unscheduled medical visits [based on the
medical procedures pricing table in Brazil (www.ramb.org.
br/CBHPM_4_Edicao.pdf)], and the antihypertensive drugs
that were administered [based on the brand-name price
(www.consultaremedios.com.br – January/2007)] were
taken into account for the cost analysis according to the
following equation:
TCCT orTCTT{HT1{2 or HT3~
X7
i~2
Cvi
where
TCCT: total cost of current treatment
TCTT: total cost of traditional treatment
HT1-2: grade 1 or 2 hypertension
HT3: grade 3 hypertension
Cv = cost of consumed medication + unscheduled
medical visits during the study.
The currency used was U.S. dollars (US$).
Other costs, such as scheduled medical visits and
laboratory exams, were the same in both regimens and
were not included in the cost analysis.
To assess the robustness of the results, the brand with the
lowest market value was used, and the C/E ratio analyses
were repeated.
Price per unit of therapeutic regimen medications (reference
price in US$/lowest price in US$):
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- amlodipine 2.5 mg = 1.82/0.47
- amlodipine 5 mg = 3.66/0.93
- amlodipine 10 mg = 6.71/1.68
- atenolol 25 mg = 0.98/0.42
- atenolol 50 mg = 1.51/0.69
- atenolol 100 mg = 2.62/1.25
- clonidine 0.1 mg = 0.20/0.20
- enalapril 10 mg = 2.40/0.70
- enalapril 20 mg = 2.40/1.04
- furosemide 40 mg = 0.72/0.31
- hydralazine 50 mg = 0.39/0.39
- hydrochlorothiazide 6.25 mg = 0.06/0.05
- hydrochlorothiazide 12.5 mg = 0.14/0.09
- losartan 25 mg = 0.93/0.87
- losartan 50 mg = 1.87/1.53
- minoxidil 10 mg = 1.48/1.48
Effectiveness measurement. For the TT and CT groups,
the effectiveness of the treatment was defined as the value
(in mm Hg) to which the drug treatment was able to reduce
the patients’ SBP and DBP after each medical visit. Thus, the
treatment’s effectiveness was represented by the following
equation:
Treatment Effectiveness~
Final BP{ Baseline BP
Incremental Cost. The incremental cost was calculated as
the ratio of the cost difference to the effectiveness difference
between the CT and the TT, which represents the additional
cost and the effectiveness gained when the CT is compared
with the TT:
CTCost{TT Cost=CT Effectiveness{TT Effectiveness
Statistical Analysis. The number of analyzed patients was
derived from the original clinical trial, which had been
calculated to meet the main objectives of that study (9). The
data from all of the patients were analyzed with an intention-
to-treat analysis. Continuous variables are descriptively
expressed as the mean ¡ standard deviation or the median
with the first and third quartiles. The categorical variables
are expressed as absolute and/or relative frequencies.
Graphically, cost-effectiveness is represented as a boxplot
on the logarithmic scale, and the median for each dataset is
Figure 1 - Flowchart of the entry and discontinuation of patients for the pharmacoeconomic analysis.
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indicated by the black center line [the first and third quartiles
are the edges of the box area, which is known as the
interquartile range (IQR)]. The extreme values (within
1.5-fold of the interquartile range from the upper or lower
quartile) are shown by the ends of the lines extending from
the IQR. Points that lie more than 1.5-fold from the IQR
are plotted individually (o). Values more than 3-fold the IQR
(*). Distributions of continuous variables and categorical
variables were compared by the Wilcoxon rank sum test and
the chi-square test, respectively. Values of p,0.05 were
considered statistically significant.
RESULTS
After the recruitment, randomization, and follow-up
period, we analyzed the results from 252 patients in the
HT1-2 group: 130 patients in the TT group and 122 patients
in the CT group. In the HT3 group, there were 82 patients in
the TT group and 84 patients in the CT group (Figure 1).
During the clinical study, three patients in the HT1-2 CT
group and 18 patients in the HT1-2 TT group dropped out
(p,0.05). In the HT3 group, 17 patients in the two treatment
arms were excluded (Figure 1).
Some demographic and clinical characteristics of the
patients are shown in Table 1 (e.g., systolic and diastolic
blood pressure values at the beginning and end of the
study). Figures 2 and 3 show the proportion of patients
upon each medical visit according to the corresponding step
of the treatment and the percentage of patients who reached
Table 1 - Demographic and clinical characteristics.
HT1-2 HT3
CT (n = 119) TT (n= 112) CT (n = 67) TT (n = 65)
Gender (%)
Male 25 24 46 37
Female 75 76 54 63
Ethnicity (%)
Caucasian 58 64 13 9
Not Caucasian 42 36 43 49
Age (y) 52¡11 54¡11 52¡11 50¡11
SBP initial (mm Hg) 155¡12 154¡12 172¡23 172¡18
SBP final (mm Hg) 125¡14* 128¡15* 131¡18* 135¡22*
DBP initial (mm Hg) 92¡10 91¡9 112¡19 111¡17
DBP final (mm Hg) 73¡11* 72¡12* 78¡12* 80¡17*
SBP: systolic blood pressure; DBP: diastolic blood pressure.
*p,0.05 between blood pressure values in the beginning and end of the
study.
Figure 2 - The percentage of patients with grade 1 or 2 hypertension (HT1-2) at each scheduled medical visit that reached the
therapeutic target blood pressure and remained in the original protocol until the end of the study. The patients are divided according
to their treatment group.
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the therapeutic target blood pressure in the HT1-2 and HT3
groups, respectively.
Importantly, there was no difference in the percentage of
patients with controlled BP between the two treatment
regimens (TT and CT) at the end of the study in either the
HT1-2 group (71% and 76.7%, respectively) or the HT3
group (56.1% and 55.9%, respectively). In the HT1-2 group,
however, the therapeutic target was reached in a higher
proportion of patients compared with the HT3 group. When
we analyzed the number of patients who used OCTs and
remained in the protocol until the end of the study, we
found that there was no difference regarding the TT and CT
Figure 3 - The percentage of patients with grade 3 hypertension (HT3) at each scheduled medical visit that reached the therapeutic
target blood pressure and remained in the original protocol until the end of the study. The patients are divided according to their
treatment group.
Table 2 - Cost-effectiveness (C/E) ratios based on the purchase prices of the brand-names in patients with grade 1 or 2
(HT1-2) or grade 3 (HT3) hypertension. The data were analyzed according to the antihypertensive regimen used [i.e., the
traditional treatment (TT) versus the current treatment (CT)].
C/E HT1-2 p-value HT3 p-value
CT (n= 122) TT (n = 130) CT (n = 84) TT (n = 82)
US$/mm Hg SBP 83 (59 – 117) 41 (30 – 66) 0.0001 76 (56 – 124) 75 (55 – 141) 0.8446
US$/mm Hg DBP 120 (92 – 224) 61 (43 – 101) 0.0001 95 (74 – 129) 99 (69 – 171) 0.4570
Median (first - third quartiles); SBP: systolic blood pressure; DBP: diastolic blood pressure.
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regimens in the HT1-2 and HT3 groups, but a higher
percentage of HT3 patients ended the study using OCTs.
Table 2 shows the C/E ratios [i.e., the cost (in US$) of
reducing BP by 1 mm Hg at the end of the study]. For the
HT1-2 group under the CT regimen, the C/E ratio (US$/
mm Hg) was 83 (59–117) for SBP and 120 (92-224) for DBP
when the purchase price of the brand-name medication was
used to calculate the cost. These values were statistically
lower for the TT regimen than for the CT regimen, with a C/
E ratio of 41 (30–66) for SBP and 61 (43–101) for DBP
(p= 0.0001). In the HT3 group, the C/E ratios were not
statistically different between the TT and CT groups for
either SBP or DBP.
Table 3 shows that in group HT1-2, the TT cost less and
was more effective than the CT with regard to lowering
DBP. The incremental cost per mm Hg for SBP in the HT1-2
Table 3 - Incremental cost-effectiveness ratios.
HT1-2 HT3
CT (n= 122) TT (n = 130) CT (n= 84) TT (n= 82)
Total cost (US$) 314,648.76 158,206.42 286,666.47 276,660.03
Total reduction in SBP (mm Hg) 3,613.5 3,477.5 3,355 3,011
Incremental cost SBP (US$/mm Hg) 1,150.31 29.09
Total reduction in DBP (mm Hg) 2,204.8 2,350.5 2,722.5 2,590
Incremental cost DBP (US$/mm Hg) TT is dominant* 75.52
*The TT was more effective and less costly than the CT.
Figure 4 - Comparison of C/E ratios between the brand-name and lower-priced medications according to treatment regimen - current
treatment (CT) versus traditional treatment (TT) - in patients with grade 1 or 2 hypertension (HT1-2 – Panel A) or grade 3 hypertension
(HT3 – Panel B).
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group was US$ 1,150.31. In the HT-3 group, however, the
incremental cost per mm Hg for SBP and DBP was US$
29.09 and US$ 75.52, respectively.
When we analyzed variations in the market prices of the
medications (Figure 4), the TT continued to be more cost-
effective than the CT when using the lower-price brand in
HT1-2 patients. In the HT3 group, however, the C/E ratio
did not display a statistically significant difference between
the regimens.
Adverse events that occurred during the study were of
mild or moderate intensity. Interestingly, more side effects
were observed in the HT-3 group compared with the HT1-2
group. In the HT1-2 group, the patients who received the CT
regimen showed more side effects than the patients who
received the TT regimen, which was probably due to a
higher prevalence of edema (Table 4). In the HT-3 group,
however, there were no statistical differences regarding
adverse events between the CT and the TT.
DISCUSSION
In all of the analyses that we performed, the antihyper-
tensive treatment that used a thiazide combined with a beta-
blocker was more cost-effective than the combination of a
dihydropyridine-type calcium channel blocker and an
angiotensin II receptor antagonist in HT1-2 patients. There
was no difference, however, between the C/E ratios of these
treatment regimens in grade 3 hypertensive patients.
In hypertension, the reduction of blood pressure in mm
Hg is not the best measurement of the effectiveness of an
antihypertensive treatment. Nevertheless, because of the
difficulty of measuring long-term effects such as reductions
in cardiovascular disease, reductions in blood pressure are
still important data. Interestingly, several studies have
shown that a DBP reduction of 4 mm Hg per year in a
given population represents a 35 to 42% reduction in new
potential cases of stroke (10,11).
In the present study, the C/E ratios favored the use of
diuretics and beta-blockers, which corroborates the results
of previous studies (12,13,14) The higher purchase costs of
type 1 angiotensin-converting enzyme inhibitors, angioten-
sin II receptor antagonists and calcium channel blockers
have already been considered by other authors (15,16). To
the best of our knowledge, however, the present study was
the first pharmacoeconomic analysis to examine C/E ratio
differences between antihypertensive drug combinations.
Although an Italian study reported that diuretics and beta-
blockers were cost-effective, the blood pressure of a large
number of patients in that study remained uncontrolled after
using these drugs (17). By contrast, in the present study the
blood pressure of a large number of patients was controlled
regardless of the drug combination that we used, especially
in those with disease grades 1 and 2.
There was no statistically significant difference between
the TT and CT regimens in the HT3 group, which contrasts
with our results in the HT1-2 group. In the HT3 group, a
large number of patients reached the end of the study using
OCTs, which influenced the C/E ratio values even when
considering that drug costs are lower for the TT than for the
CT. Many of the patients in the HT3 group had their
treatment changed to OCTs because they experienced a
large number of side effects (Table 2), and the initial
treatments may not have adequately controlled the blood
pressure of the HT3 patients.
In Brazil, the use of epidemiological data from interna-
tional studies to perform C/E studies is common. However,
the present study included effectiveness and medication
data that were obtained in Brazilian hypertensive patients.
Although pharmacoeconomic analyses are complex, they
provide an additional tool in the treatment decision-making
process, and they should be included in the Brazilian health
system guidelines to ensure a better distribution of health
resources and to make the required medication available to
hypertensive patients based on their specific status.
Furthermore, the results of this pharmacoeconomic analysis
may also be extended to other countries because the relative
purchase prices of the analyzed classes of antihypertensive
drugs are similar.
This study had some limitations. For example, it was an
open study, and we did not perform a sensitivity analysis,
which makes it difficult to extrapolate the results. Another
limitation is the short follow-up period. Because antihyper-
tensive treatment is a life-long regimen, 12 months may not
be sufficient to reveal differences between the beneficial and
adverse effects of the treatment regimens that we studied.
After considering the limitations of the present study, we
conclude that the combination of a diuretic agent and a beta-
blocker is more cost-effective for HT1-2 patients than
treatment with a dihydropyridine-type calcium channel
blocker and an angiotensin II receptor antagonist.
Controlling blood pressure is harder in HT3 patients, and
the present results did not identify a more cost-effective
therapy; thus, the purchase cost of the medication should be
secondary when achieving blood pressure control.
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